- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.50 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x UMP: 2'-DEOXYURIDINE 5'-MONOPHOSPHATE(Non-covalent)
UMP.1: 15 residues within 4Å:- Chain A: R.300, L.442, C.445, H.446, Q.465, R.466, S.467, C.468, D.469, N.477, H.507, Y.509
- Chain B: R.425, R.426
- Ligands: CB3.3
11 PLIP interactions:9 interactions with chain A, 2 interactions with chain B- Hydrophobic interactions: A:D.469
- Hydrogen bonds: A:S.467, A:D.469, A:N.477, A:N.477, A:H.507, A:Y.509
- Salt bridges: A:R.300, A:R.466, B:R.425, B:R.426
UMP.5: 16 residues within 4Å:- Chain A: R.425, R.426
- Chain B: R.300, L.442, C.445, H.446, Q.465, R.466, S.467, C.468, D.469, G.473, N.477, H.507, Y.509
- Ligands: CB3.7
11 PLIP interactions:2 interactions with chain A, 9 interactions with chain B- Salt bridges: A:R.425, A:R.426, B:R.300, B:R.466
- Hydrophobic interactions: B:D.469
- Hydrogen bonds: B:Q.465, B:S.467, B:D.469, B:N.477, B:N.477, B:H.507
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
NDP.2: 29 residues within 4Å:- Chain A: V.9, A.10, I.17, G.18, I.19, N.21, G.22, L.23, W.25, G.55, R.56, K.57, T.58, S.61, V.77, S.78, S.79, S.80, A.103, V.126, G.127, G.128, A.129, G.130, L.131, Y.132, A.134, V.157
- Ligands: BOD.4
21 PLIP interactions:21 interactions with chain A- Hydrophobic interactions: A:T.58
- Hydrogen bonds: A:A.10, A:I.17, A:I.19, A:G.22, A:G.55, A:R.56, A:R.56, A:K.57, A:T.58, A:T.58, A:S.61, A:S.61, A:S.79, A:S.80, A:S.80, A:G.128, A:A.129, A:G.130, A:G.130
- Salt bridges: A:R.56
NDP.6: 27 residues within 4Å:- Chain B: V.9, A.10, I.17, G.18, I.19, N.21, G.22, L.23, W.25, G.55, R.56, K.57, T.58, V.77, S.79, S.80, A.103, S.104, V.126, G.127, G.128, A.129, G.130, L.131, A.134, V.157
- Ligands: BOD.8
20 PLIP interactions:20 interactions with chain B- Hydrophobic interactions: B:T.58
- Hydrogen bonds: B:A.10, B:I.17, B:I.19, B:N.21, B:G.22, B:R.56, B:R.56, B:K.57, B:T.58, B:S.79, B:S.80, B:L.105, B:G.128, B:A.129, B:G.130, B:G.130, B:L.131
- Salt bridges: B:R.56, B:K.57
- 2 x CB3: 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID(Non-covalent)
CB3.3: 17 residues within 4Å:- Chain A: K.327, R.328, V.329, F.330, E.337, I.358, N.362, D.469, L.472, G.473, F.476, N.477, Y.509, R.559, M.564, A.565
- Ligands: UMP.1
15 PLIP interactions:15 interactions with chain A- Hydrophobic interactions: A:F.330, A:I.358, A:I.358, A:L.472, A:F.476
- Hydrogen bonds: A:D.469, A:Y.509, A:R.559, A:A.565, A:A.565, A:A.565
- Salt bridges: A:K.327, A:D.469, A:R.559
- pi-Stacking: A:F.476
CB3.7: 16 residues within 4Å:- Chain B: R.328, V.329, F.330, E.337, I.358, W.359, N.362, D.469, L.472, G.473, F.476, N.477, Y.509, M.564, A.565
- Ligands: UMP.5
14 PLIP interactions:14 interactions with chain B- Hydrophobic interactions: B:F.330, B:I.358, B:I.358, B:F.476, B:F.476
- Hydrogen bonds: B:F.330, B:D.469, B:F.476, B:A.565, B:A.565, B:A.565
- Salt bridges: B:K.327, B:D.469
- pi-Stacking: B:F.476
- 2 x BOD: 5-{4-[3-(2-methoxypyrimidin-5-yl)phenyl]piperazin-1-yl}pyrimidine-2,4-diamine(Non-covalent)
BOD.4: 14 residues within 4Å:- Chain A: V.8, V.9, A.10, L.23, H.27, D.31, F.32, F.35, M.62, P.63, V.126, Y.132, T.147
- Ligands: NDP.2
7 PLIP interactions:7 interactions with chain A- Hydrophobic interactions: A:L.23
- Hydrogen bonds: A:V.8, A:Y.132, A:T.147, A:T.147
- Salt bridges: A:D.31
- pi-Stacking: A:F.32
BOD.8: 14 residues within 4Å:- Chain B: V.8, V.9, A.10, L.23, H.27, D.31, F.32, F.35, M.62, P.63, V.126, Y.132, T.147
- Ligands: NDP.6
7 PLIP interactions:7 interactions with chain B- Hydrophobic interactions: B:F.32, B:P.63
- Hydrogen bonds: B:V.8, B:T.147, B:T.147
- Salt bridges: B:D.31
- pi-Stacking: B:H.27
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Thomas, S.B. et al., Identification of selective, brain penetrant Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis. To Be Published
- Release Date
- 2018-08-22
- Peptides
- Bifunctional dihydrofolate reductase-thymidylate synthase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 3.50 Å
- Oligo State
- homo-dimer
- Ligands
- 2 x UMP: 2'-DEOXYURIDINE 5'-MONOPHOSPHATE(Non-covalent)
- 2 x NDP: NADPH DIHYDRO-NICOTINAMIDE-ADENINE-DINUCLEOTIDE PHOSPHATE(Non-covalent)
- 2 x CB3: 10-PROPARGYL-5,8-DIDEAZAFOLIC ACID(Non-covalent)
- 2 x BOD: 5-{4-[3-(2-methoxypyrimidin-5-yl)phenyl]piperazin-1-yl}pyrimidine-2,4-diamine(Non-covalent)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Thomas, S.B. et al., Identification of selective, brain penetrant Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis. To Be Published
- Release Date
- 2018-08-22
- Peptides
- Bifunctional dihydrofolate reductase-thymidylate synthase: AB
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
B